Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 4/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.32 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16197865 | 0.87 | CYP2D6 (0.52) | CYP2D6CYP2C19BACE1 | |
| SCHEMBL1221870 | 0.86 | — | — | |
| SCHEMBL15044027 | 0.86 | — | — | |
| SCHEMBL3321903 | 0.86 | — | — | |
| SCHEMBL18342160 | 0.84 | — | — | |
| SCHEMBL3781636 | 0.84 | — | — | |
| SCHEMBL3180096 | 0.84 | — | — | |
| SCHEMBL20482750 | 0.84 | — | — | |
| SCHEMBL20595525 | 0.84 | — | — | |
| SCHEMBL18125948 | 0.84 | SLC22A6 (0.57) | CYP2D6CYP2C19SLC22A6GABRR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8165271-A | — | — | None | — | — | JP | disclosed |
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2024-05-16 | — | — | US | disclosed |
| US-11897970-B2 | Antibacterial products | THE UNIVERSITY OF LIVERPOOL (GB) | 2024-02-13 | — | — | US | disclosed |
| EP-4284801-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | Janssen Biotech, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-3426248-B1 | BICYCLIC ARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3654968-B1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230025834-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| EP-3938377-A1 | CYCLIC PEPTIDE ANTIBIOTICS | F. Hoffmann-La Roche AG (CH) | 2022-01-19 | — | — | EP | disclosed |
| US-11207312-B2 | Metallo-beta-lactamase inhibitors and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210139539-A1 | NEW ANTIBACTERIAL PRODUCTS | THE UNIVERSITY OF LIVERPOOL (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-3426248-A1 | BICYCLIC ARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | Merck Sharp & Dohme Corp. (US) | 2019-01-16 | — | — | EP | disclosed |
| US-20180244656-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-08-30 | — | — | US | disclosed |
| EP-3313832-A1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2017155765-A1 | BICYCLIC ARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2016210215-A1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016196393-A2 | AUTOPHAGY-INHIBITING COMPOUNDS AND USES THEREOF | PRESAGE BIOSCIENCES, INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| EP-1663245-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-7192943-B2 | Cephem compounds | ASTELLAS PHARMA INC. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20050096306-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-05-05 | — | — | US | disclosed |
| JP-H08165271-A | PRODUCTION OF 2-HYDROXY-1,3-PROPANEDIAMINEPOLYCARBOXYLIC ACID, ITS ALKALI SALT AND BIODEGRADABLE CHELATE REAGENT CONTAINING THE SAME | NITTO CHEM IND CO LTD | 1996-06-25 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | SIK2, SIK1, SGK2 | CYP2D6 4759/4885CYP2C19 4811/4885SLC22A6 3023/4885 |
| US-20210139539-A1 | NEW ANTIBACTERIAL PRODUCTS | DBI, MRPL21, NRDC | CYP2D6 1525/4885CYP2C19 1825/4885SLC22A6 1000/4885 |
| US-20230025834-A1 | CYCLIC PEPTIDE ANTIBIOTICS | NPPA, LNPEP, CLPP | CYP2D6 4358/4885CYP2C19 4280/4885SLC22A6 2566/4885 |
| US-20050096306-A1 | Cephem compounds | CEP170, ASS1, C1S | CYP2D6 384/4885CYP2C19 85/4885SLC22A6 603/4885 |
| US-11897970-B2 | Antibacterial products | DBI, PDIA5, ABCB11 | CYP2D6 1114/4885CYP2C19 1415/4885SLC22A6 771/4885 |
| US-20180244656-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MLX, ZFX, MMP12 | CYP2D6 704/4885CYP2C19 380/4885SLC22A6 408/4885 |
| US-11207312-B2 | Metallo-beta-lactamase inhibitors and methods of use thereof | MLX, MMP12, SLC11A2 | CYP2D6 555/4885CYP2C19 405/4885SLC22A6 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.